More tools:Markets·Screener·Research·Chat

Enlivex Ltd. Ordinary Shares (ENLV) Financial Statements

Enlivex Ltd. Ordinary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG005ZL1Z95
XNAS · usd
1.11▲ 0.01 (0.91%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt—
Trading Information
Previous Close1.10
Day's Range1.06 – 1.19
52-Week Range0.43 – 7.64
Volume189.2K
Avg Volume414.1K
Share Statistics
Shares Outstanding
Employees34
ExchangeXNAS
Listed2014-07-31
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Enlivex Ltd. Ordinary Shares (ENLV)
What is Enlivex Ltd. Ordinary Shares's Market Cap?
Enlivex Ltd. Ordinary Shares's Market Cap is $263.5M, based on as-reported figures from SEC (XBRL) filings.
What is Enlivex Ltd. Ordinary Shares's Trailing P/E?
Enlivex Ltd. Ordinary Shares's Trailing P/E is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Enlivex Ltd. Ordinary Shares's Revenue (TTM)?
Enlivex Ltd. Ordinary Shares's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Enlivex Ltd. Ordinary Shares's Net Income (TTM)?
Enlivex Ltd. Ordinary Shares's Net Income (TTM) is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Enlivex Ltd. Ordinary Shares's EBITDA?
Enlivex Ltd. Ordinary Shares's EBITDA is -$14.7M, based on as-reported figures from SEC (XBRL) filings.
What is Enlivex Ltd. Ordinary Shares's Diluted EPS (TTM)?
Enlivex Ltd. Ordinary Shares's Diluted EPS (TTM) is 5.20, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Operating expenses:
Research and development expenses, net (note 19a)
General and administrative expenses (note 19b)
Other expenses (note 19c)
Total
Operating loss
Income on digital assets, net (note 19d)
Change in fair value of digital assets purchase option (note 7)
Finance income, net (note 19e)
Income (loss) before taxes on income
Taxes on income (note 15)
Net income (loss)
Basic earnings (loss) per share (in Dollars per share)
Diluted earnings (loss) per share (in Dollars per share)